Drug glossary Targeted therapy

Ruxolitinib Jakafi, Opzelura

Used in colorectal cancer outside its approved indication. It appears in 4 clinical trials.

Oral JAK1 JAK2
See its trials
United States Off-label
European Union EMA approved Since 2012
Spain Hospital use Used off-label in colorectal cancer

What it is

Ruxolitinib is a selective Janus kinase (JAK) inhibitor that blocks JAK1 and JAK2 signaling pathways. While approved for certain blood cancers and inflammatory conditions, ruxolitinib is being explored in colorectal cancer through combination approaches with other targeted agents. In CRC, it is primarily tested alongside MEK inhibitors like trametinib to target multiple oncogenic pathways simultaneously.

How it works

Ruxolitinib selectively inhibits JAK1 and JAK2 kinases, which are critical components of the JAK-STAT signaling pathway involved in cell proliferation, survival, and immune responses. By blocking these kinases, ruxolitinib disrupts cytokine signaling that can promote tumor growth and inflammation in the tumor microenvironment.

Molecular targets

Common side effects

ThrombocytopeniaAnemiaNeutropeniaDiarrheaPeripheral edemaFatigueDizzinessHeadache

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.